Spruce Biosciences confirms TA-ERT BLA submission on track for Q4 2026
Spruce Biosciences says positive pre-BLA meetings with the FDA support its plan to submit a BLA for TA-ERT in Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Spruce Biosciences confirms positive FDA pre-BLA meetings for ta-ert
Spruce Biosciences says its pre-BLA meetings with the FDA for ta-ert were positive and that its BLA submission remains on track for Q4 2026.